Webinars & Presentations

Applications

Cell Therapy
CRISPR/Gene Editing
Cell Based Assays
Protein Production
Gene Editing

Cell Types

Dendritic Cells
ESC
Insect Cell Lines (S2/Sf9/Sf21)
HEK293
Cancer Cell Lines
CHO
iPSCs
NPCs/NSCs
NK Cells
PBMCs
HSPCs
T Cells

TCR/CAR T

Gene Therapy

CAR T

Presentation: Next-Generation DNA NanoVectors – an alternative Vector Platform for the safe, rapid and persistent manufacture of recombinant T cells for Autologous T Cell Immunotherapy

• Best in class DNA Vector that combine mitotic stability with low immunogenicity • Efficiently produced in bacterial cells at high yield and purity without post-processing • Provide robust transgene expression in every cell and model system available • Efficacy comparable to state-of-the-art clinically utilized vectors with short, efficient and economical manufacturing time

CRISPR/Gene Editing

Cell Based Assays

T Cells

Development of a genome-wide CRISPR screen in CD4+ T cells to identify drug targets for immune-mediated inflammatory diseases

Apr 7, 2021 – Dr. Ricky Trigg – Immune-mediated inflammatory diseases (IMIDs) are a group of disorders characterized by tissue inflammation as a result of dysregulated immune responses. This webinar will showcase the development of a genome-wide CRISPR screen in primary T cells to identify drug targets for IMIDs, and will cover key areas of workflow optimization, including lentiviral transduction, Cas9 electroporation in bulk cell populations, and fluorescence-activated cell sorting.

Protein Production

CHO

BioProcess International: Ask the Expert Webcast

Employing a transient transfection strategy using Flow Electroporation enabled efficient, cost-effective evaluation of HIV vaccine candidates accelerating the therapeutic product into animal studies months ahead of schedule.

Cell Therapy

CRISPR/Gene Editing

HSPCs

Correction of the Sickle Cell Disease Mutation with CRISPR/Cas9

October 15th, 2020 – Dr. Mark DeWitt – Project Scientist at the University of California, Los Angeles – Sickle Cell Disease (SCD), one of the world’s most common genetic disorders, causes anemia and progressive multiorgan damage that typically shortens lifespan by decades; currently there is no broadly applicable curative therapy. A universal curative therapy for SCD would address a critical unmet medical need in the United States and worldwide. During this webinar, Dr. Mark DeWitt will discuss the development of a CRISPR/Cas9-based strategy to correct the mutation in CD34+ HSPCs harvested from SCD patients.

Gene Editing

HEK293

iPSCs

T Cells

Other Mammalian Cell Lines

Scalable Manufacturing and Nanovesicle Delivery of CRISPR-Cas9 Ribonucleoproteins Using a cGMP- Compliant Cell Engineering Platform

September 17, 2020 – Peter Gee – MaxCyte Field Application Scientist – CRISPR-Cas9 has tremendous potential as a therapeutic tool for treating human diseases. However, prolonged expression of the nuclease and gRNA from viral vectors in an in vivo context may cause unwanted off-target activity and immunogenicity. To overcome these safety issues, a system was recently developed for transient delivery of CRISPR-Cas9 ribonucleoprotein (RNP), recruiting Cas9 protein by chemically-induced dimerization and sgRNA via a viral RNA packaging signal into extracellular nanovesicles.

Cell Therapy

CRISPR/Gene Editing

NK Cells

PBMCs

T Cells

Webinar: Overview of a Flexible, Clinically Adaptable, Non-viral Approaches to CAR TCR Methodologies

Abstract: In this webinar for scientists and researchers, Rama Shivakumar, a senior scientist at MaxCyte Inc., will highlight powerful case studies that demonstrate the successful use of MaxCyte’s clinically validated, scalable electroporation system in the pre-clinical and clinical scale engineering of resting and activated T cells using a mesothelin specific CARmRNA; in the enhancement of NK cell cytotoxicities against B cell malignancies using an antiCD19 CAR mRNA; in the transposon (Piggybac and Sleeping Beauty) based gene delivery for manufacture of CAR-T cells ; and finally in the gene editing of T cells for improving the efficacy of a TCR immunotherapy. August 04, 2020.

Protein Production

HEK293

Therapeutic Antibody Discovery by Mammalian Display

iONTAS’s innovative antibody discovery technology can save time and effort downstream by addressing antibody developability issues during the initial phase of biotherapeutic discovery.

Protein Production

CHO

Winning the Race: Decreasing Protein Development Timelines with Scalable Cell Engineering

The critical role of a flexible, reproducible and scalable technology for cellular engineering in the rapid development of protein therapeutics.

Cell Therapy

NK Cells

Improving NK Cell-based Cancer Immunotherapy via mRNA Electroporation

Natural Killer (NK) cells are cytotoxic lymphocytes that can kill tumor-transformed and infected cells. – December 2017

CRISPR/Gene Editing

Cell Based Assays

iPSCs

NPCs/NSCs

High Transfection Efficiency of Human Induced Pluripotent Stem Cells and Their Derivatives

High transfection efficiencies of plasmids expressing CRISPR/Cas9 in hiPSCs and iPSC-derived cell lines improved genomic DNA editing efficiency in hiPSCs by up to 10-fold.